males) referred to the Centre for Extrapyramidal Disorders of the Istituto Neurologico "C.Besta" in a period of 16 months. Most patients were studied as out-patients. More severe cases were admitted to improve drug schedule and disease control and were evaluated as in-patients.
The diagnosis of idiopathic Parkinson's disease was established by the presence of clinical features (resting tremor, bradykinesia, rigidity and postural instability) and response to antiparkinsonian drugs. No patient had undergone surgical treatment. Patients with secondary Parkinsonism or with clinical evidence of involvement of other major neuroanatomical system (pyramidal and cerebellar signs, oculomotor abnormalities) were excluded.
The diagnosis ofdementia was based on DSM-III criteria22 (see also Results) and was agreed upon by two examiners in each single case relying on interviews with patients and relatives. Particular care was taken to assess whether confusion, delusions and hallucinations were present and whether they could be modified by drug schedule variations. Lack of improvement of cognitive functions after dose reduction or drug withdrawal where appropriate, led to a diagnosis of dementia despite the clinical evidence of hallucinations, delusion and confusion. In Twenty-one Parkinsonian patients (14 28%) were classified as demented according to DSM-III criteria (table 1). All demented Parkinsonian patients (PD-D) had had cognitive impairment for at least 6 months. They had social and occupational impairment due to mental but not to motor deficits. All PD-D had clinical and historical evidence of change in personality, impairment of abstraction and memory problems. No PD-D patients had aphasic, apraxic or agnosic disturbances at clinical examination. Table 1 shows the main clinical and therapeutic characteristics of Parkinson's disease and PD-D patients. Among Parkinson's disease patients, nine were still untreated while the other 117 were on medication: 21 were on dopamine-agonists, nine were on anticholinergics, 39 were on levodopa plus a peripheral decarboxylase inhibitor (PDI) alone, 20 were on levodopa + PDI and dopamine-agonists, 22 were on levodopa + PDI and anticholinergics and finally six patients were on levodopa therapy + PDI and both dopamine-agonists and anticholinergics. The mean daily levodopa dosage was 646-01, SD 273-93 mg. PD-D subjects were all on levodopa plus a peripheral decarboxylase inhibitor alone (nine subjects) or in combination with dopamine-agonists (six subjects) or with anticholinergics (six subjects). The mean daily levodopa dosage was 741-80, SD 300-91 mg.
PD-D patients were older and had more severe disability than Parkinson's disease patients. On-off, wearing off phenomena and abnormal involuntary movements (AIMS) did not differ between groups. Pyschotic side effects (hallucinations, delusions and Girotti, Soliveri, Carella, Piccolo, Caffarra, Musicco, Caraceni Table 3 shows the characteristics of psychotic side effects in Parkinson's disease and PD-D patients. In the Parkinson's disease group, psychotic side effects were similar to those found in the PD-D group even though less severe. Table 4 shows the distribution of dementia according to age in our population. As it is evident, dementia was more prominent in older age groups. Psychometric evaluation could not be performed in five PD-D patients because of severe motor impairment and cognitive decline. More of the PD-D patients showed hyperkinesia and motor fluctuations than did demented Parkinsonians in other reports.7"9 A previous study of our group30 did not show a significant difference in the prevalence of on-off phenomena and hyperkinesia in younger onset Parkinsonians than in other Parkinsonians but stressed the earlier onset of those phenomena in younger patients. A longer disease duration in our demented patients may therefore account for the higher frequency of hyperkinesia and on-off phenomena in our demented patients. In agreement with other reports,7 29 our PD-D patients showed greater Parkinsonian impairment as well as increased susceptibility to psychotic disturbances induced by levodopa, anticholinergics and dopamine-agonists. 3 32 It may be argued that the greater symptom severity of the PD-D group might be partly due to a lower mean levodopa dosage. That was not the case; the mean levodopa dosage for PD-D patients was 741 80, SD 300-91 mg, whereas mean levodopa dosage for Parkinson's disease patients was 646-01, SD ± 273-93 (p = ns). This supports the notion that greater disease severity accounted for greater symptom severity in PD-D and that suboptimal treatment was not the cause of the difference in symptom severity.
Moreover, none of the PD-D patients was on monotherapy with either dopamine-agonists or anticholinergics, whereas many of the Parkinson's disease patients were either on dopamine agonists alone (22 subjects) or on anticholinergics alone (nine subjects) or even still untreated (nine subjects).
With this respect it is well-known that only mildly impaired Parkinsonian patients may obtain the advantage of anticholinergics or dopamine agonists because these drugs are less effective than levodopa.
Interestingly, Parkinson's disease patients showed fewer confusional states and psychotic symptoms despite the fact that the percentage of Parkinson's disease patients treated with anticholinergics alone or in combination with levodopa was similar (31%) to that of PD-D patients (28%) Recently, Della Sala et al4 and Brown and Marsden35 reported no alterations of visuo-spatial abilities in Parkinson's disease. However, they based their conclusions on the study of a selected sample of Parkinsonians. In that regard, it is appropriate here to consider some methodological aspects of our present study to appreciate better the significance of our results based on the analysis of a large sample of patients. Only a small percentage of our Parkinson's disease patients had performances inferior to 2 SD of controls even in the most affected tests. Brown and Marsden, reviewing the subject matter of cognitive impairment in Parkinson's disease,37 concluded that their performance was within normal limits showing only a slight impairment when compared with controls. Accordingly, the consistent variability20 in cognitive performances of Parkinson's disease in different studies is probably due to a selection bias in some studies including in some series patients with global cognitive impairment who may well have been regarded as demented.
In our series, some patients appeared to be more compromised in some specific tests, as became clear when patients were classified according to the mean and SD ofthe controls, suggesting that those tests may have revealed general cognitive deterioration better than others. Therefore, the existence of specific cognitive deficits along with the presence in our series of patients with borderline dementia, may have accounted for the worse performance of the whole group of Parkinson's disease patients in the tests more sensitive to mental decay.
Our present study, which was descriptive in nature, did not allow the definition ofsubgroups38 with specific alterations for instance in memory, cognitive planning or visuo-spatial deficits. However, our results in PD-D may shed some light on the characteristics ofcognitive impairment in Parkinson's disease. Our PD-D showed a global cognitive decline involving all cognitive aspects. Nevertheless, the outline of their cognitive impairment followed that of Parkinson's disease. In 
